JP2023521032A - コロナウイルス感染症を処置するためのフーリンインヒビター - Google Patents

コロナウイルス感染症を処置するためのフーリンインヒビター Download PDF

Info

Publication number
JP2023521032A
JP2023521032A JP2022560236A JP2022560236A JP2023521032A JP 2023521032 A JP2023521032 A JP 2023521032A JP 2022560236 A JP2022560236 A JP 2022560236A JP 2022560236 A JP2022560236 A JP 2022560236A JP 2023521032 A JP2023521032 A JP 2023521032A
Authority
JP
Japan
Prior art keywords
methyl
pyridin
oxy
dichlorophenyl
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022560236A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521032A5 (enExample
Inventor
ウィルコクソン，キース
マーパ，クラウディーン
オドルジン，タチャーナ
サイーダ，ネイビル，ジー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BP Asset V Inc
Original Assignee
BP Asset V Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BP Asset V Inc filed Critical BP Asset V Inc
Publication of JP2023521032A publication Critical patent/JP2023521032A/ja
Publication of JP2023521032A5 publication Critical patent/JP2023521032A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2022560236A 2020-04-02 2021-04-01 コロナウイルス感染症を処置するためのフーリンインヒビター Pending JP2023521032A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063004365P 2020-04-02 2020-04-02
US63/004,365 2020-04-02
US202063013382P 2020-04-21 2020-04-21
US63/013,382 2020-04-21
US202163156058P 2021-03-03 2021-03-03
US63/156,058 2021-03-03
PCT/US2021/025382 WO2021202874A1 (en) 2020-04-02 2021-04-01 Furin inhibitors for treating coronavirus infections

Publications (2)

Publication Number Publication Date
JP2023521032A true JP2023521032A (ja) 2023-05-23
JP2023521032A5 JP2023521032A5 (enExample) 2024-04-11

Family

ID=75660352

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022560236A Pending JP2023521032A (ja) 2020-04-02 2021-04-01 コロナウイルス感染症を処置するためのフーリンインヒビター

Country Status (9)

Country Link
US (1) US20230149401A1 (enExample)
EP (1) EP4125897A1 (enExample)
JP (1) JP2023521032A (enExample)
KR (1) KR20220167296A (enExample)
CN (1) CN115666567A (enExample)
AU (1) AU2021249149A1 (enExample)
CA (1) CA3173921A1 (enExample)
IL (1) IL296885A (enExample)
WO (1) WO2021202874A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115385983A (zh) * 2022-01-11 2022-11-25 嘉兴安谛康生物科技有限公司 氮杂双环类化合物及其制备方法、药物组合物和用途
DE102023126563A1 (de) * 2023-09-28 2025-04-03 Philipps-Universität Marburg, Körperschaft des öffentlichen Rechts Hemmstoffe der Proproteinkonvertase Furin, Verfahren zu deren Herstellung und Verwendung

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008505050A (ja) * 2003-12-10 2008-02-21 エイジェンシー フォア サイエンス テクノロジー アンド リサーチ Ｓａｒｓコロナウイルスｓタンパク質およびその使用
WO2019215341A1 (en) * 2018-05-11 2019-11-14 Glaxosmithkline Intellectual Property Development Limited Furin inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2687024A1 (en) 2007-05-09 2009-02-19 Burnham Institute For Medical Research Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008505050A (ja) * 2003-12-10 2008-02-21 エイジェンシー フォア サイエンス テクノロジー アンド リサーチ Ｓａｒｓコロナウイルスｓタンパク質およびその使用
WO2019215341A1 (en) * 2018-05-11 2019-11-14 Glaxosmithkline Intellectual Property Development Limited Furin inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JEAN KAORU MILLET ET AL.: "Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-med", PNAS, vol. 111 (42), JPN7025001479, 2014, pages 15214 - 15219, ISSN: 0005694408 *
SOEREN LUKASSEN ET AL.: "SARS-CoV-2 receptor ACE2 and TMPRSS2 are predominantly expressed in atransient secretory ", BIORXIV, JPN7025001478, 30 March 2020 (2020-03-30), ISSN: 0005694407 *
YOSHIYUKI YAMADA ET AL.: "Proteolytic Activation of the Spike Protein at a Novel RRRR/S Motif Is Implicated in F", JOURNAL OF VIROLOGY, vol. 83 (17), JPN7025001480, 2009, pages 8744 - 8758, ISSN: 0005694409 *

Also Published As

Publication number Publication date
CA3173921A1 (en) 2021-10-07
US20230149401A1 (en) 2023-05-18
IL296885A (en) 2022-12-01
AU2021249149A1 (en) 2022-10-20
CN115666567A (zh) 2023-01-31
KR20220167296A (ko) 2022-12-20
WO2021202874A1 (en) 2021-10-07
EP4125897A1 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
JP2023521753A (ja) 抗ウイルス療法
Hu et al. Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses
CN114641485A (zh) 用于治疗covid-19的化合物和方法
AU2021361044A9 (en) Tricyclic heterobifunctional compounds for degradation of targeted proteins
Li et al. JMX0207, a niclosamide derivative with improved pharmacokinetics, suppresses Zika virus infection both in vitro and in vivo
Xu et al. Design, synthesis, and biological evaluation of substituted 4, 6-dihydrospiro [[1, 2, 3] triazolo [4, 5-b] pyridine-7, 3′-indoline]-2′, 5 (3 H)-dione analogues as potent NS4B inhibitors for the treatment of dengue virus infection
CN110494141A (zh) 含有被取代的多环性吡啶酮衍生物及其前药的药物组合物
Urvashi et al. Development of azaindole-based frameworks as potential antiviral agents and their future perspectives
TW202208445A (zh) 用於治療及預防ＳＡＲＳ－ＣｏＶ－２感染的人源化ＡＣＥ２－Ｆｃ融合蛋白
US20230149401A1 (en) Furin inhibitors for treating coronavirus infections
WO2025096856A1 (en) Covalent cereblon ligands
CA3210278A1 (en) Compositions and methods for viral sensitization
US20250304559A1 (en) Ether-Linked Antiviral Compounds
US12059413B2 (en) Methods of inhibiting viruses using compositions targeting TSG101-ubiquitin interaction
JP2025523594A (ja) 修飾された融合タンパク質及び核酸コンストラクト
Essalmani et al. Implications of Spike-glycoprotein processing at S1/S2 by Furin, at S2’by Furin and/or TMPRSS2 and shedding of ACE2: cell-to-cell fusion, cell entry and infectivity of SARS-CoV-2
Guo et al. Inhibition of Human Coronaviruses by Piperidine-4-Carboxamides
Hopstaken et al. Development of a Multivalent Macrocyclic Peptide that Shows In Vivo Protection Against SARS-CoV-2 Infection Following Intranasal Administration
Huang et al. Potential inhibitors for blocking the interaction of the coronavirus SARS-CoV-2 2 spike protein and its host cell receptor ACE2
Rodrigo Quintanar et al. Ubiquitin-like modifier-activating enzyme 1 interacts with Zika virus NS5 and promotes viral replication in the infected cell
Moliner-Morro Characterisation of nanobodies directed against emerging viruses
Kissai I. Chemical Biology Tools to Modulate the Innate Immune System: Cyclic GMP-AMP Synthase Inhibitors and Phase Separation Modulators II. Structural Studies of Vimentin-Binding Small Molecules
Jerak Isolation and Characterization of Broadly Neutralizing Antibodies to Coronaviruses
US8911935B2 (en) Mitochondria and human immunodefiency virus type 1
Merino Characterization of the SARS-CoV-2 S Glycoprotein: Emerging Mutations and Host Antibody Responses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240401

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250403

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250925